We are live on ! Find out more
Stempoint Capital

Stempoint Capital Portfolio holdings

AUM $560M Turnover 64.34%
1-Year Est. Return 146.87%
This Fund
S&P 500
This Quarter Est. Return
+25.39%
1 Year Est. Return
+146.87%
3 Year Est. Return
+725.67%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$375M
AUM Growth
–
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
39.49%
Holding
67
New
–
Increased
–
Reduced
–
Closed
–
Avg Time Held Equity + Options
0 years
Top 10 Avg Time Held Equity + Options
0 years
Top 20 Avg Time Held Equity + Options
0 years
Avg Time Held Equity only
0 years
Top 10 Avg Time Held Equity only
0 years
Top 20 Avg Time Held Equity only
0 years

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 91.59%
2 Miscellaneous 8.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ROIV icon
1
Roivant Sciences
ROIV
$28B
$24.4M 6.5%
2,169,116
– –
2023 Q4
0 quarters
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$785M
$23.7M 6.31%
1,094,494
– –
2023 Q4
0 quarters
ACLX icon
3
DELISTED
Arcellx
ACLX
$17.4M 4.64%
313,604
– –
2023 Q4
0 quarters
MRUS icon
4
DELISTED
Merus
MRUS
$13.8M 3.68%
501,806
– –
2023 Q4
0 quarters
IMVT icon
5
Immunovant
IMVT
$6.57B
$13.6M 3.62%
322,015
– –
2023 Q4
0 quarters
FOLD icon
6
DELISTED
Amicus Therapeutics
FOLD
$12.2M 3.27%
862,815
– –
2023 Q4
0 quarters
PTGX icon
7
Protagonist Therapeutics
PTGX
$7.92B
$11.8M 3.14%
513,681
– –
2023 Q4
0 quarters
IMTX icon
8
Immatics
IMTX
$879M
$10.7M 2.87%
1,020,214
– –
2023 Q4
0 quarters
BBIO icon
9
BridgeBio Pharma
BBIO
$14.8B
$10.3M 2.74%
253,948
– –
2023 Q4
0 quarters
CABA icon
10
Cabaletta Bio
CABA
$202M
$10.2M 2.73%
450,706
– –
2023 Q4
0 quarters
MLTX icon
11
MoonLake Immunotherapeutics
MLTX
$942M
$10.1M 2.7%
167,851
– –
2023 Q4
0 quarters
ARGX icon
12
CALL
argenx
ARGX
$58.2B
$10.1M 2.69%
26,484
– –
2023 Q4
0 quarters
MRK icon
13
Merck
MRK
$330B
$9.7M 2.59%
89,016
– –
2023 Q4
0 quarters
JNJ icon
14
Johnson & Johnson
JNJ
$651B
$9.6M 2.55%
61,011
– –
2023 Q4
0 quarters
CRNX icon
15
DELISTED
Crinetics Pharmaceuticals
CRNX
$8.88M 2.37%
249,575
– –
2023 Q4
0 quarters
LLY icon
16
Eli Lilly
LLY
$1.2T
$8.78M 2.34%
15,067
– –
2023 Q4
0 quarters
VTGN icon
17
VistaGen Therapeutics
VTGN
$7.56M
$8.76M 2.34%
1,790,182
– –
2023 Q4
0 quarters
ARQT icon
18
Arcutis Biotherapeutics
ARQT
$3.33B
$8.38M 2.24%
2,594,536
– –
2023 Q4
0 quarters
SYRE icon
19
Spyre Therapeutics
SYRE
$8.88B
$8.15M 2.17%
378,766
– –
2023 Q4
0 quarters
TEVA icon
20
CALL
Teva Pharmaceutical Industries
TEVA
$45.8B
$7.32M 1.95%
701,597
– –
2023 Q4
0 quarters
IRON icon
21
Disc Medicine
IRON
$3.42B
$7.24M 1.93%
125,429
– –
2023 Q4
0 quarters
LNTH icon
22
Lantheus
LNTH
$6.68B
$6.75M 1.8%
108,911
– –
2023 Q4
0 quarters
LEGN icon
23
Legend Biotech
LEGN
$2.96B
$6.3M 1.68%
104,650
– –
2023 Q4
0 quarters
ATXS icon
24
DELISTED
Astria Therapeutics
ATXS
$6.16M 1.64%
856,952
– –
2023 Q4
0 quarters
INSM icon
25
Insmed
INSM
$31B
$5.38M 1.44%
173,579
– –
2023 Q4
0 quarters

Similar funds

Stempoint Capital's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for Stempoint Capital, which disclosed 67 positions worth $375M. Its ten largest holdings account for 39% of the portfolio.

Its largest position is Roivant Sciences: 2,169,116 shares worth $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, followed by Miscellaneous.

  • Stempoint Capital's ten largest holdings make up 39% of its $375M portfolio in Q4 2023.
  • Stempoint Capital disclosed 67 positions in Q4 2023, its first 13F filing on record.

Based on Stempoint Capital's 13F filing for Q4 2023, filed 13 Feb 2024.